LTFS
SYRE icon

Ladenburg Thalmann Financial Services’s Spyre Therapeutics SYRE Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$6K Hold
31
– – ﹤0.01% 4719
2019
Q3 		$6K Hold
31
– – ﹤0.01% 4620
2019
Q2 		$5K Hold
31
– – ﹤0.01% 4723
2019
Q1 		$6K Hold
31
– – ﹤0.01% 4595
2018
Q4 		$6K Hold
31
– – ﹤0.01% 4523
2018
Q3 		$8K Buy
+31
New +$7.24K ﹤0.01% 4402

Other funds holding SYRE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ladenburg Thalmann Financial Services's SYRE Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services held its Spyre Therapeutics (SYRE) position steady in Q4 2019 at 31 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #4719.

Ladenburg Thalmann Financial Services first reported a position in SYRE in Q3 2018 and has held it in 6 quarters since. The position peaked at $8K in Q3 2018. 68 funds tracked by Wall St. Rank hold SYRE as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 31 shares of Spyre Therapeutics worth $6K as of Q4 2019.
  • Ladenburg Thalmann Financial Services left its Spyre Therapeutics share count unchanged in Q4 2019.
  • Spyre Therapeutics made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #4719 holding.
  • Ladenburg Thalmann Financial Services first reported a position in Spyre Therapeutics in Q3 2018 and has held it in 6 quarters since.
  • Ladenburg Thalmann Financial Services's Spyre Therapeutics position peaked at $8K in Q3 2018.
  • 68 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.